Previous Close | 1.0800 |
Open | 1.0800 |
Bid | 1.0700 x 900 |
Ask | 1.1000 x 1000 |
Day's Range | 1.0600 - 1.1100 |
52 Week Range | 0.9000 - 2.5300 |
Volume | |
Avg. Volume | 162,472 |
Market Cap | 46.931M |
Beta (5Y Monthly) | 0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6330 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for VCNX
Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases including Alzheimer’s ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that result
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for poster presentation related to its ongoing Phase 1/2a SIGNAL-AD study of pepinemab in patients with early Alzheimer’s Disease during the upcoming 2022 Alzheimer’s Association International Conference, taking place
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...